Genomic Health, Inc.
301 Penobscot Drive
About Genomic Health, Inc.About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
404 articles about Genomic Health, Inc.
Genomic Health Release: Oncotype DX Genomic Prostate Score (GPS) Test Predicts 10-Year Risk Of Prostate Cancer-Specific Death And Metastases In Patients With Early-Stage Disease
Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) On Medicare Coverage For Use Of Oncotype DX Genomic Prostate Score In Patients With Favorable Intermediate-Risk Prostate Cancer.
Genomic Health To Announce First Quarter 2017 Financial Results And Host Conference Call On Tuesday, May 9, 2017
Genomic Health Release: Oncotype DX Predicts 10-Year Risk Of Developing Metastatic Prostate Cancer In Low- And Intermediate-Risk Patients
Genomic Health Release: Published Outcomes Results From SEER Registries Indicates That Many Node-Positive Breast Cancer Patients Can Avoid Chemotherapy Based On Oncotype DX Results
Genomic Health Unveils A Wealth Of Data For The Oncotype DX Breast Cancer Test, Reinforcing Its Value In Improving Patient Outcomes And Leading To More Cost-Effective Management
Genomic Health Release: Four New Studies Of Oncotype DX Genomic Prostate Score (GPS) Reconfirm Value Of Test In Guiding Early-Stage Prostate Cancer Risk Assessment And Treatment Selection
Genomic Health Announces 2016 Fourth Quarter And Year-End Financial Results, Provides 2017 Financial Outlook
Genomic Health To Announce Fourth Quarter And Year-End 2016 Financial Results And Host Conference Call On Tuesday, February 14, 2017
Genomic Health Announces Inclusion Of Oncotype DX In The 8th Edition Of American Joint Committee On Cancer (AJCC) Criteria For Breast Cancer Staging
Genomic Health Announces Results From Multiple Oncotype DX Studies, Reinforcing Its Impact In Delivering Precision Medicine To Breast Cancer Patients Around The World
Genomic Health Reports Third Consecutive Quarter Of Double-Digit Revenue Growth In Announcement Of Third Quarter 2016 Financial Results
Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX Prostate Cancer Test Predicts Risk Of Metastasis And Mortality
Genomic Health Release: Comprehensive Economic Analysis Published In Reviews In Urology Demonstrates Oncotype DX Prostate Cancer Test Leads To Substantial Cost Savings And Increase In Active Surveillance
Genomic Health To Announce Third Quarter 2016 Financial Results And Host Conference Call On Tuesday, November 1, 2016
Genomic Health Presents Robust Analytical Validation Study Results Of Oncotype SEQ Liquid Biopsy Mutation Panel
Genomic Health Release: Multiple Oncotype DX Presentations At ESMO 2016 Congress Reinforce Its Unique Clinical Utility With Prospective Outcomes Results In Over 63,000 Breast Cancer Patients
Genomic Health Reinforces Global Leadership In Genomic-Based Diagnostics With Presentation Of Nine Personalized Medicine Studies Conducted In Six Countries At ESMO 2016 Congress